A man holding a bag over his shoulder with headphones on looking into the camera. A man holding a bag over his shoulder with headphones on looking into the camera.

How AUSTEDO May Help

In clinical studies, AUSTEDO (deutetrabenazine) tablets effectively reduced the involuntary movements of tardive dyskinesia (TD).1

AUSTEDO is FDA-approved to treat tardive dyskinesia in adults and treats movements in the face, tongue, or other body parts that can’t be controlled. AUSTEDO is thought to work in parts of the brain related to the involuntary movements of TD.1-3

An AUSTEDO patient, Angi, shares her tardive dyskinesia diagnosis story and tardive dyskinesia treatment. An AUSTEDO patient, Angi, shares her tardive dyskinesia diagnosis story and tardive dyskinesia treatment.

Patient Insights

Treating TD with AUSTEDO
(deutetrabenazine) tablets

Hear how Angi’s sister encouraged her to tell her doctor about the effects of TD, and what her life is like now after starting treatment for TD.

A guide to talking
with your doctor

Customize and download the Doctor Discussion Guide to help prepare to discuss symptoms of tardive dyskinesia with your doctor.

A cellphone being used to complete the Doctor Discussion Guide. A cellphone being used to complete the Doctor Discussion Guide.

In clinical studies of AUSTEDO1,4,5:

Improvement check icon.

Physicians reported that people taking AUSTEDO showed an improvement in their involuntary movements.

Medication icon.

People taking AUSTEDO were able to continue with their mental health medications like antipsychotics or antidepressants.

Calendar icon.

In one clinical study, AUSTEDO significantly reduced the involuntary movements of TD after 12 weeks of treatment vs placebo, with improvements beginning to be seen at 2 weeks.

Tell your doctor about all of the medicines you take, including prescription and over-the-counter medications, vitamins, and herbal supplements.

Do not take AUSTEDO if you are taking any of the following medicines:

  • A monoamine oxidase inhibitor (MAOI) medicine. Do not take an MAOI within 14 days after you stop taking AUSTEDO. Do not start AUSTEDO if you stopped taking an MAOI in the last 14 days. Ask your healthcare provider or pharmacist if you are not sure.
  • Reserpine. Do not take medicines that contain reserpine (such as Serpalan® and Renese®-R) with AUSTEDO. If your healthcare provider plans to switch you from taking reserpine to AUSTEDO, you must wait at least 20 days after your last dose of reserpine before you start taking AUSTEDO.
  • Tetrabenazine (Xenazine®). If your healthcare provider plans to switch you from tetrabenazine (Xenazine®) to AUSTEDO, take your first dose of AUSTEDO on the day after your last dose of tetrabenazine (Xenazine®).
  • Valbenazine (Ingrezza®).
AUSTEDO® Copay program.
AUSTEDO® Copay program.
AUSTEDO® copay program.
AUSTEDO® copay program.

For eligible individuals with a valid AUSTEDO prescription. Please note this offer is not available for patients eligible for Medicare, Medicaid or any other government payer coverage. Please review complete Terms and Conditions.

You could pay $0 for your first 30 days and $0 monthly

Find financial support

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information Parsippany, NJ. Teva Neuroscience, Inc. 2. Warikoo N, Schwartz TL, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention. Nova Science Publishers, Inc; 2013:235-258. 3. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther.2018;12:1215–1238. doi:10.2147/DDDT.S133205 4. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 5. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry.. 2017;4(8):595-604. Published online June 28, 2017. doi: 10.1016/S2215-0366(17)30236-5